Charles Dietrich, MD
Associate Professor
Gynecology Oncology Division
University of Kentucky
 

Upon completion of this activity, participants will be able to: 

1. Describe the rationale for using hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of peritoneal malignancies.
2.  Review the current literature supporting the use of HIPEC in ovarian cancer.
3.  Explain the intraoperative technique for administering HIPEC.

Disclosure of Financial Interest - Summary to Learners

All planners, faculty, and others in control of educational content are required to disclose all their financial relationships
with ineligible companies within the prior 24 months. An ineligible company is defined as one whose primary business is
producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships
are relevant if the educational content an individual can control is related to the business lines or products of the ineligible
company.
None of the planners, faculty, and others in control of educational content for this educational activity have relevant
financial relationship(s) to disclose with ineligible companies.
The material presented in this course represents information obtained from the scientific literature as well as the clinical
experiences of the speakers. In some cases, the presentations might include discussion of investigational agents and/or offlabel
indications for various agents used in clinical practice. Speakers will inform the audience when they are discussing
investigational and/or off-label uses.
Disclosure of a relationship is not intended to suggest or condone commercial bias in any presentation, but it is made to
provide participants with information that might be of potential importance to their evaluation of a presentation.